𝐒𝐞𝐞𝐝-𝐬𝐭𝐚𝐠𝐞 𝐢𝐬𝐧’𝐭 𝐨𝐮𝐫 𝐮𝐬𝐮𝐚𝐥 𝐩𝐥𝐚𝐲𝐛𝐨𝐨𝐤. 𝐀𝐫𝐢𝐚𝐅𝐥𝐨𝐰 𝐦𝐚𝐝𝐞 𝐮𝐬 𝐫𝐞𝐭𝐡𝐢𝐧𝐤 𝐢𝐭.

At ekwithree we don’t normally invest this early. We typically back more established businesses, but every so often a company comes along that’s worth breaking your own rules for.

AriaFlow is one of them. And here’s what sets it apart: this isn’t an AI tool built by founders fresh out of university. It’s built by industry veterans who have spent years inside regulatory affairs (Axel Schnuetgen, Daniel Koppers, Alexander Schwind). They know exactly where the hours go, and where the risk sits. That’s why it solves the real problem rather than a demo of it: the platform turns a company’s own templates into controlled workflows with trusted sources, full traceability and expert review to produce regulated medical and life-sciences documents that hold up to scrutiny. Less assembly, more judgment.

For us at ekwithree, this is a first step into the intersection of AI, life sciences and healthcare and it reflects something we’ve long believed: technology creates the most value when it’s paired with deep domain expertise and pointed at a real business problem.

New stage, same conviction. We’re proud to back the AriaFlow team on what comes next.